19th week of 2010 patent applcation highlights part 52 |
Patent application number | Title | Published |
20100120786 | Piperazine Derivatives - This invention relates to novel compounds that are piperazine derivatives, and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel piperazine compounds that are derivatives of the chemokine CCR5 receptor antagonist, vicriviroc. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administering chemokine CCR5 receptor antagonists, such as vicriviroc. The invention also relates to the use of one or more of the disclosed compounds as reagents in analytical studies involving vicriviroc. | 2010-05-13 |
20100120787 | MODIFICATION OF AMYLOID-BETA LOAD IN NON-BRAIN TISSUE - The present invention relates to methods and compositions for modulating levels of amyloid-β peptide (Aβ) exhibited by non-neuronal (i.e., peripheral) cells, fluids, or tissues. The invention also relates to modulation of Aβ levels via selective modulation (e.g., inhibition) of γ-secretase activity. The invention also relates to methods of preventing, treating or ameliorating the symptoms of a disorder, including but not limited to an Aβ-related disorder, by administering a compound that result in the modulation of γ-secretase in a non-neuronal tissue, either directly or indirectly to prevent, treat or ameliorate the symptoms of a brain Aβ disorder, such as Alzheimer's disease. | 2010-05-13 |
20100120788 | IDENTIFICATION OF POLYNUCLEOTIDES FOR PREDICTING ACTIVITY OF COMPOUNDS THAT INTERACT WITH AND/OR MODULATE PROTEIN TYROSINE KINASES AND/OR PROTEIN TYROSINE KINASE PATHWAYS IN PROSTATE CELLS - The present invention describes polynucleotides that have been discovered to correlate to the relative intrinsic sensitivity or resistance of cells, e.g., prostate cell lines, to treatment with compounds that interact with and modulate, e.g., inhibit, protein tyrosine kinases, such as, for example, members of the Src family of tyrosine kinases, e.g., Src, Fgr, Fyn, Yes, Blk, Hck, Lck and Lyn, as well as other protein tyrosine kinases, including, Bcr-abl, Jak, PDGFR, c-kit and Eph receptors. These polynucleotides have been shown to have utility in predicting the resistance and sensitivity of prostate cell lines to the compounds. The expression level or phosphorylation status of some polynucleotides is regulated by treatment with a particular protein tyrosine kinase inhibitor compound, thus indicating that these polynucleotides are involved in the protein tyrosine kinase signal transduction pathway, e.g., Src tyrosine kinase. Such polynucleotides, whose expression levels correlate highly with drug sensitivity or resistance and which are modulated by treatment with the compounds, comprise polynucleotide predictor or marker sets useful in methods of predicting drug response, and as prognostic or diagnostic indicators in disease management, particularly in those disease areas, e.g., prostate cancer, in which signaling through the protein tyrosine kinase pathway, such as the Src tyrosine kinase pathway, is involved with the disease process. | 2010-05-13 |
20100120789 | Compound - There is provided a compound having Formula I | 2010-05-13 |
20100120790 | DPP-IV INHIBITOR INCLUDING BETA-AMINO GROUP, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR PREVENTING AND TREATING DIABETES OR OBESITY - The present invention provides a novel heterocyclic compound containing a beta-amino group, a method for preparing the same, and a pharmaceutical composition comprising the same heterocyclic compound or a pharmaceutically acceptable salt thereof as an active ingredient. The heterocyclic compound of the present invention exhibits excellent DPP-IV inhibitory activity and bioavailability and therefore can be useful for the prophylaxis or treatment of DPP-IV-related diseases such as diabetes or obesity. | 2010-05-13 |
20100120791 | CYCLOHEXYL SULFONAMIDE DERIVATIVES - The present invention relates to compounds of formula I | 2010-05-13 |
20100120792 | Substituted 2,3,4,5-Tetrahyrdo-1H-Pyrido[4,3-B]Indoles, Methods for the Production and Use Thereof - The invention relates to antagonists of serotonin 5-HT | 2010-05-13 |
20100120793 | Pyrrolidines - This invention relates to a class of pyrrolidine compounds of formula (I), and pharmaceutically acceptable derivatives thereof, to their use in medicine, to compositions containing them, and to processes for their preparation. It also relates to intermediates used in the preparation of such compounds and derivatives. In particular the compounds of formula (I) are useful for the treatment of EP2-mediated conditions, such as endometriosis, uterine fibroids (leiomyomata), menorrhagia, adenomyosis, primary and secondary dysmenorrhoea (including symptoms of dyspareunia, dyschexia and chronic pelvic pain), chronic pelvic pain syndrome. | 2010-05-13 |
20100120794 | Cycloalkylamino Acid Derivatives - The invention relates to compounds of formula I | 2010-05-13 |
20100120795 | POWDERS FOR RECONSTITUTION - This invention relates to powders for reconstitution comprising the NNRTI TMC278 dispersed in certain water-soluble polymers, which can be used in the treatment of HIV infection. | 2010-05-13 |
20100120796 | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF HYPERURICEMIA RELATED HEALTH CONSEQUNECES - Disclosed herein are methods of delaying the onset or treating diabetes that comprises administering a uric acid lowering agent. The inventors have made the remarkable discovery that elevated uric acid levels are not a corollary to insulin resistance, but rather a primary mediator of insulin resistance. Specifically exemplified are methods that involve administering to a patient susceptible to development of diabetes a composition comprising a uric acid lowering agent in a regimen that maintains serum uric acid levels below at least 5.5 mg/dl, or below at least 5.2 mg/dl. | 2010-05-13 |
20100120797 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS - This invention relates to novel purinyl derivatives and their use as potassium channel modulating agents. Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels. | 2010-05-13 |
20100120798 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY - The invention provides compounds of the formula (I) having PKA and PKB kinase inhibiting compounds of the formula (I): GP 1 J T 2 J N 4 R N H (I) or salts, solvates, tautomers or N-oxides thereof, wherein (1) GP is a group GP1: HET 2a a Q G (HNCO)f 7 (R)x N * (GP1) (2) GP is a group GP2: 10 (R)r O 2a a QG (CH2)w N V H N * (GP2) wherein HET is a monocyclic or bicyclic heterocyclic group containing up to 4 heteroatom ring members; the ring V is a monocyclic or bicyclic heteroaryl group of 5 to 10 ring members; and J1, J2, R4, R7, R10, Q2a, Ga, x, w and f are as defined in the claims | 2010-05-13 |
20100120799 | PURINE DERIVATIVES AS IMMUNOMODULATORS - Compounds of formula (I): | 2010-05-13 |
20100120800 | AGENT FOR PREVENTING RECURRENCE OF CEREBROVASCULAR DISORDER AND AGENT FOR AMELIORATING TROUBLES FOLLOWING CEREBROVASCULAR DISORDER AND INHIBITING PROGRESS THEREOF - There is provided an agent for preventing the recurrence of cerebrovascular disorder and an agent for ameliorating troubles following cerebrovascular disorder and inhibiting the progress thereof which contain a compound having an angiotensin II antagonistic activity, a prodrug thereof or a salts thereof. | 2010-05-13 |
20100120801 | AKT AND P70 S6 KINASE INHIBITORS - The present invention provides AKT and p70 S6 kinase inhibitors of the formula: | 2010-05-13 |
20100120802 | Novel Anti-Inflammatory and Analgesic Heterocyclic Amidines that Inhibit Nitrogen Oxide (NO) Production - Heterocyclic amidines with anti-inflammatory and analgesic activity that inhibit nitrogen oxide production, of formula (I): | 2010-05-13 |
20100120803 | 3,4-DIHYDROQUINAZOLINE DERIVATIVES - The present invention relates to 3,4-dihydroquinazoline derivatives, a process of preparing them and a pharmaceutical composition including them. The 3,4-dihydroquinazoline derivatives of the present invention have excellent T-type calcium channel blocking effect and anti-cancer activity. | 2010-05-13 |
20100120804 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors - A process for the preparation of a compound of formula (I) | 2010-05-13 |
20100120805 | Fused Bicyclic and Tricyclic Pyrimidine Compounds as Tyrosine Kinase Inhibitors - Fused bicyclic or tricyclic compounds of formula (I): | 2010-05-13 |
20100120806 | CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES - Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including, but not limited to, malignant melanomas, solid tumors, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, hepatic cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, chronic myelogenous leukemia, leukemias, papillary thyroid carcinoma, non-small cell lung cancer, mesothelioma, hypereosinophilic syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, diabetic retinopathy, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocytosis, mast cell leukemia, and diseases caused by PDGFR-α kinase, PDGFR-β kinase, c-KIT kinase, cFMS kinase, c-MET kinase, and oncogenic forms, aberrant fusion proteins and polymorphs of any of the foregoing kinases. | 2010-05-13 |
20100120807 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY - The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119. | 2010-05-13 |
20100120808 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE - Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the δ opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other δ opioid receptor-mediated conditions. | 2010-05-13 |
20100120809 | ARYL HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS - Compounds of formula I: | 2010-05-13 |
20100120810 | COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES - The present invention relates to methods and compositions that affect the GTP-binding activity of members of the Rho family GTPases, preferably Rac GTPases (Rac1, Rac1b, Rac2 and/or Rac3). | 2010-05-13 |
20100120811 | LONG-ACTING INJECTABLE ANALGESIC FORMULATIONS FOR ANIMALS - Long acting injectable analgesic formulations and methods for providing long lasting pain relief in animals are disclosed. | 2010-05-13 |
20100120812 | Medicinal Compositions Comprising Buprenorphine And Naltrexone - An analgesic composition, in parenteral unit dosage form or in a unit dosage form suitable for delivery via the dermis or mucosa, comprises buprenorphine and an amount of naltrexone such that the ratio by weight of buprenorphine to naltrexone delivered to or reaching the plasma of a patient is in the range 100:1 to 5000:1. The analgesic action of the buprenorphine is potentiated by the low dose of naltrexone. Also provided are a method of treatment of pain and the use of buprenorphine and naltrexone for the manufacture of a medicament. | 2010-05-13 |
20100120814 | Crystalline and Amorphous Forms of Naltrexone Hydrochloride - The present invention relates to novel crystalline forms of naltrexone hydrochloride including hydrated and solvated forms and a novel amorphous form. The invention also describes methods of preparing the various crystalline forms. The present invention also relates to pharmaceutical compositions containing crystalline and amorphous forms of naltrexone hydrochloride, as well as methods of treating addictive behavior by administering the pharmaceutical compositions. | 2010-05-13 |
20100120815 | STABLE SOLID PREPARATION CONTAINING 4,5-EPOXYMORPHINAN DERIVATIVE - It is an object of the present invention to provide a stable solid preparation comprising a 4,5-epoxymorphinan derivative or a pharmacologically acceptable acid addition salt thereof as an effective ingredient. | 2010-05-13 |
20100120816 | CAMPTOTHECIN DERIVATIVES WITH ANTITUMOR ACTIVITY - Novel camptothecin derivatives having antitumor activity, the processes for the preparation thereof, the use thereof as antitumor drugs and pharmaceutical compositions containing them. | 2010-05-13 |
20100120817 | AZONAFIDE DERIVED TUMOR AND CANCER TARGETING COMPOUNDS - An azonafide-based compound of Formula I, a composition comprising the compound, and a method of using the compound to deliver a cytotoxic azonafide derivative to a cell, as well as related compounds and methods for the use thereof to pre-pare an azonafide-based compound of Formula I. | 2010-05-13 |
20100120818 | SUBSTITUTED TETRAHYDROPYRROLOQUINOLINES - Compounds of the formula (I), in which R | 2010-05-13 |
20100120819 | METHOD OF REDUCING IMIQUIMOD IMPURITY FORMATION - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 2010-05-13 |
20100120820 | METHOD OF TREATING ACTINIC KERATOSIS - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 2010-05-13 |
20100120821 | METHOD OF TREATING GENITAL OR PERI-ANAL WARTS - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 2010-05-13 |
20100120822 | METHOD OF CONTROLLING FORMATION OF IMIQUIMOD IMPURITIES (BHA COMPARATOR) - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 2010-05-13 |
20100120823 | METHOD OF TREATING BASAL CELL CARCINOMA - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 2010-05-13 |
20100120824 | METHOD OF PREPARING A PHARMACEUTICAL CREAM AND MINIMIZING IMIQUIMOD IMPURITY FORMATION - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 2010-05-13 |
20100120825 | METHOD OF TREATING MOLLESCUM CONTAGIOSUM - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 2010-05-13 |
20100120826 | METHOD OF INDUCING CYTOKINE BIOSYNTHESIS - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 2010-05-13 |
20100120827 | X-FOLD LESS IMIQUIMOD IMPURITIES AT TWO MONTHS BETWEEN REFINED AND COMPENDIAL - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 2010-05-13 |
20100120828 | METHOD OF INDUCING INTERFERON BIOSYNTHESIS - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 2010-05-13 |
20100120829 | X-FOLD LESS IMIQUIMOD IMPURITIES AT SIX MONTHS BETWEEN REFINED AND COMPENDIAL - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 2010-05-13 |
20100120830 | PHARMACEUTICAL CREAM HAVING SIMILAR OR LESS LEVELS OF IMIQUIMOD IMPURITY FORMATION AS CREAM WITH BHA (COMPARATOR) - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 2010-05-13 |
20100120831 | METHODS FOR IMPROVING IMIQUIMOD AVAILABILITY AT TWO MONTHS, FOUR MONTHS AND SIX MONTHS BETWEEN REFINED AND COMPENDIAL - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 2010-05-13 |
20100120832 | METHOD OF PREPARING A PHARMACEUTICAL CREAM AND MINIMIZING IMIQUIMOD IMPURITY FORMATION (AT LEAST FOUR MONTHS STORAGE) - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 2010-05-13 |
20100120833 | METHOD OF PREPARING A PHARMACEUTICAL CREAM AND MINIMIZING IMIQUIMOD IMPURITY FORMATION (AT LEAST SIX MONTHS STORAGE) - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 2010-05-13 |
20100120834 | REDUCTION OF IMIQUIMOD IMPURITIES AT FOUR MONTHS USING REFINED OLEIC ACID - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 2010-05-13 |
20100120835 | PHARMACEUTICAL CREAM WITH REDUCED IMIQUIMOD IMPURITIES AT FOUR MONTHS USING REFINED OLEIC ACID - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 2010-05-13 |
20100120836 | METHOD OF TREATING A DERMAL AND/OR MUCOSAL ASSOCIATED CONDITION - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 2010-05-13 |
20100120837 | METHOD OF TREATING A MUCOSAL AND/OR DERMAL ASSOCIATED CONDITION - Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. | 2010-05-13 |
20100120838 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS - This invention relates to compounds of the Formula (I): | 2010-05-13 |
20100120839 | PYRAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION - There is provided compounds of formula I, | 2010-05-13 |
20100120840 | Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents - Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer. | 2010-05-13 |
20100120841 | BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF - Provided is an ORL-1 receptor agonist having improved bioavailability based on superior metabolic stability and strong and high selectivity, as compared to conventional compounds. A compound represented by the formula (I) | 2010-05-13 |
20100120842 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION - The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells. | 2010-05-13 |
20100120843 | PHARMACEUTICAL COMPOSITION FOR TREATING ALCOHOL-INDUCED LIVER INJURY COMPRISING (4S,5S)-5-FLUOROMETHYL-5-HYDROXY-4-(AMINO)-DIHYDROFURAN-2-ONE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF - The present invention relates to a pharmaceutical composition for treating alcohol-induced liver injury comprising (4S,5S)-5-fluoromethyl-5-hydroxy-4-({[(5R)-5-isopropyl-3-(isoquinolin-1-yl)-4,5-dihydro-5-isoxazolyl]carbonyl}amino)-dihydrofuran-2-one or pharmaceutically acceptable salt thereof, and a use thereof. | 2010-05-13 |
20100120844 | TETRAHYDROISOQUINOLINE COMPOUND - The present invention relates a specific tetrahydroisoquinoline compound which is useful as a chemokine receptor type 3 (CCR3) antagonist, and a pharmaceutical composition comprising the same as an active ingredient. The tetrahydroisoquinoline compound of the present invention is useful for the treatment or prevention of a disease in which CCR3 participates. | 2010-05-13 |
20100120845 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS - The invention relates to a compound of formula (I): | 2010-05-13 |
20100120846 | TRPV1 ANTAGONISTS - Disclosed herein are compounds of formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, | 2010-05-13 |
20100120847 | STYRYLQUINOLINES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC USES - The present invention concerns new substituted styrylquinolines, their process of preparation and their therapeutic uses as integrase inhibitors and/or for the treatment and/or prevention of HIV. | 2010-05-13 |
20100120848 | STABLE PHARMACEUTICAL FORMULATIONS OF MONTELUKAST SODIUM - The invention encompasses stable pharmaceutical compositions comprising montelukast or salts thereof and methods of preparing the same. | 2010-05-13 |
20100120849 | Compositions for Treating Hyperproliferative Vascular Disorders and Cancers - The present invention relates to a pharmaceutical composition for preventing or treating hyperproliferative vascular disorders, and a pharmaceutical anticancer composition comprising the compound represented by the Formula 1. The present compounds exhibit IC | 2010-05-13 |
20100120850 | Quinoline Derivatives, Pharmaceutical Compositions Comprising Them, and Their Use in Treating Central Nervous System and Peripheral Diseases - Compounds of Formula (I) wherein R | 2010-05-13 |
20100120851 | PRENYLTRANSFERASE INHIBITORS FOR OCULAR HYPERTENSION CONTROL AND THE TREATMENT OF GLAUCOMA - The invention concerns in one embodiment a method of treating glaucoma or elevated intraocular pressure comprising administering a pharmaceutically effective amount of a composition comprising at least one prenyltransferase inhibitor. In another embodiment, the invention concerns a composition for the treatment of elevated intraocular pressure and glaucoma comprising a pharmaceutically effective amount of a prenyltransferase inhibitor. | 2010-05-13 |
20100120852 | AROYL-PIPERIDINE DERIVATIVES AND METHOD OF TREATING DISORDERS INDUCED BY SUBSTANCE P - The invention relates to a method of administering N-(3,5-bis-trifluoromethyl-benzoyl)-2-benzyl-4-(quinoloylamino)-piperidines of the formula | 2010-05-13 |
20100120853 | Derivatives of Hypoestoxide and Related Compounds - Novel diterpene compounds, in particular, hypoestoxide-related compounds, are provided in pure form or as contained in the native plant source, for treatment and prophylaxis of cancer, inflammatory diseases, hyperlipidemias, malaria, and diabetes mellitus. Embodiments also pertain to methods for using the hypoestoxide-related compounds to treat various diseases and symptoms associated with those diseases. | 2010-05-13 |
20100120854 | TGF-BETA INHIBITORS - The present invention provides crystalline 2-(6-methyl-pyridin-2-yl)-3-[6-amido-quinolin-4-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole monohydrate. | 2010-05-13 |
20100120855 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS - Inhibitors of HCV replication of formula (I), the N-oxides, salts, and stereochemically isomeric forms thereof, wherein each dashed line (represented by | 2010-05-13 |
20100120856 | Derivatives of the Aminated Hydroxyquinoline Class For Treating Cancers - The invention relates to compounds of the animated hydroxyquinoline type capable of preventing the migration of metastases or tumoral cells. Such compounds are useful for treating cancers. | 2010-05-13 |
20100120857 | USE OF TRIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS - Provided are tris-quaternary ammonium compounds which are modulators of nociception and pain. | 2010-05-13 |
20100120858 | Piperidine Derivatives - The invention relates to compounds of Formula (I) | 2010-05-13 |
20100120859 | NOVEL CASE OF RENIN INHIBITORS - The present invention relates to piperidine-based renin inhibitor compounds having carboxylate or carboxylic acid terminal groups, and their use in treating cardiovascular events and renal insufficiency. | 2010-05-13 |
20100120860 | THIA(DIA)ZOLES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS - The present invention relates to [1-(benzyl)-piperidin-4-yl]-([1,3,4]thiadiazol-2-yl)-amine and [1-(benzyl)-piperidin-4-yl]-(thiazol-2-yl)-amine derivatives of formula (I) that are fast dissociating dopamine 2 receptor antagonists, processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. The compounds find utility as medicines for treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect without motor side effects. | 2010-05-13 |
20100120861 | BENZOIC ACID INHIBITORS OF ATP-SENSITIVE POTASSIUM CHANNELS - The present invention relates to new benzoic acid inhibitors of ATP-sensitive potassium channel activity, pharmaceutical compositions thereof, and methods of use thereof. | 2010-05-13 |
20100120862 | MONOCYCLIC COMPOUNDS AND THEIR USE AS TRPV1 LIGANDS - The invention relates to compounds of formula I | 2010-05-13 |
20100120863 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES - The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved. | 2010-05-13 |
20100120864 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS - The invention relates to compounds of formula I | 2010-05-13 |
20100120865 | Organic compounds - The present invention concerns a compound of formula (I), or a pharmaceutically acceptable salt, or solvate thereof, wherein the groups Ri-Rs are defined in the description, to compositions and use of the compounds in the treatment of diseases ameloriated by inhibition of phosphatidylinositol 3-kinase. | 2010-05-13 |
20100120866 | PROCESS FOR PRODUCING AMIDE COMPOUND - There is provided a process for producing an amide compound having an excellent harmful arthropod-controlling activity and represented by the formula (III): wherein R | 2010-05-13 |
20100120867 | METHOD OF TREATMENT - Improvements in the treatment of patients suffering from frequent heartburn are provided by a treatment regimen comprising administration of an effective daily amount of lansoprazole or a pharmaceutically acceptable salt thereof for up to 14 days. | 2010-05-13 |
20100120868 | Process For Preparing Solid Dosage Forms of Rosiglitazone Maleate - The invention relates to a process for preparing a solid pharmaceutical composition rosiglitazone maleate, comprising the step of adsorption of rosiglitazone maleate onto carrier particles (C) during a dry mixing process. | 2010-05-13 |
20100120869 | COMPOUNDS AND METHODS FOR PKC THETA INHIBITION - The present invention provides a method of selectively inhibiting PKCθ in the presence of PKCδ, by administering to a subject in need thereof, a therapeutically effective amount of a compound of Formula I. The present invention also provides a method of inhibiting cytokine synthesis in a T cell, a method of inhibiting T cell proliferation, and a method of inhibiting the replication of and cytokine production by T lymphocytes, while not stimulating or inhibiting the replication of B lymphocytes. | 2010-05-13 |
20100120870 | Dispersible pesticidal compositions - Soluble granule pesticidal compositions comprise Flonicamid, a dispersant, and a wetting agent are disclosed. | 2010-05-13 |
20100120871 | HAIR CARE COMPOSITIONS, METHODS, AND ARTICLES OF COMMERCE THAT CAN INCREASE THE APPEARANCE OF THICKER AND FULLER HAIR - Hair care compositions, methods, and articles of commerce that can increase the appearance of thicker and fuller hair. Such compositions can be applied to any areas where a thicker and fuller hair appearance is desired, such as the scalp or face. The present invention also relates to methods of marketing such compositions. | 2010-05-13 |
20100120872 | ORGANIC COMPOUNDS AND THEIR USES - The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases. | 2010-05-13 |
20100120873 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR AGE-RELATED MACULAR DEGENERATION - An object of the present invention is to find a novel medicinal use of 2-phenyl-1,2-benzisoselenazol-3(2H)-one or a salt thereof. 2-Phenyl-1,2-benzisoselenazol-3(2H)-one or a salt thereof exhibits an excellent inhibitory effect on neovascularization in the choroid and also has a protective effect on retinal pigment epithelial cell damage, and therefore is useful as a prophylactic or therapeutic agent for age-related macular degeneration. | 2010-05-13 |
20100120874 | HETEROCYCLIC GAMMA SECRETASE MODULATORS - The invention relates to methods for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome which comprise administering a therapeutically effective amount of a compound of formula I | 2010-05-13 |
20100120875 | USE OF 4-[(4-THIAZOLYL)PHENOXY]ALKOXY-BENZAMIDINE DERIVATIVES FOR TREATMENT OF OSTEOPOROSIS - A method of treating osteoporosis comprising administering to a subject a composition comprising a compound, 4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine or a salt thereof, is described. A method of inhibiting osteoclast activity and stimulating osteoblast activity in a subject also is described. | 2010-05-13 |
20100120876 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON-LIKE PEPTIDE (GLP-1) COMPOUND OR A MELANOCORTIN-4 RECEPTOR (MC4) AGONIST PEPTIDE - The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide. | 2010-05-13 |
20100120877 | ADDITIONAL THERAPEUTIC USE - The invention relates to the use of an AT | 2010-05-13 |
20100120878 | FORMULATION - This invention relates to mixtures of triazole compounds and in particular to the use of such mixtures in non-crystallising compositions. It relates to mixtures that are concentrated solutions and also to the use of the concentrated solutions in water diluted form. Furthermore, it relates to the use of such mixtures for agricultural or materials protection purposes and to the use of one triazole compound to prevent or delay crystallisation of a second triazole compound. | 2010-05-13 |
20100120879 | INSECTICIDES AS SAFENER FOR FUNGICIDES WITH PHYTOTOXIC ACTION - The present invention relates to the use of insecticides which are selected among GABA antagonists and nicotin receptor agonists/antagonists, if appropriate in combination with at least one gibberellin, as safener for fungicides which have a phytotoxic effect. Moreover, the invention relates to a method of reducing or preventing the phytotoxic effect of fungicides on plants treated therewith or on plants whose seeds or growth substrate have been or are treated with these fungicides. The invention finally also relates to compositions which comprise at least one GABA antagonist, at least one azole fungicide or strobilurin fungicide and, if appropriate, at least one gibberellin, and to compositions which comprise at least one nicotin receptor agonist/antagonist, at least one azole fungicide or strobilurin fungicide and, if appropriate, at least one gibberellin. | 2010-05-13 |
20100120880 | PROCESS TO PREPARE NEW SUBSITUTED 1H-BENZO[d]IMIDAZOL-2(3H)-ONES, NEW INTERMEDIATES AND THEIR USE AS BACE 1 INHIBITORS - The invention relates to a new process leading to new substituted 1H-benzo[d]imidazol-2(3H)-ones of formula III and III′, to pharmaceutical compositions comprising them and to their use as therapeutic agents, particularly as BACE 1 inhibitors in the treatment of Alzheimer disease. | 2010-05-13 |
20100120881 | CHEMICAL COMPOUNDS - The present invention relates to imidazoline derivatives and their use as insecticidal, acaricidal, molluscicidal and nematocidal agents. The invention also extends to insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising such imidazoline derivatives, and to methods of using such derivatives and/or compositions to combat and control insect, acarine, mollusc and nematode pests. In particular the present invention relates to imidazolines with alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl or heterocyclyl substituents. | 2010-05-13 |
20100120882 | PHENOXYMETHYL IMIDAZOLINE DERIVATIVES AND THEIR USE AS PESTICIDES - The present invention relates to imidazoline derivatives and their use as insecticidal, acaricidal, molluscicidal and nematocidal agents. The invention also extends to insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising such imidazoline derivatives, and to methods of using such derivatives and/or compositions to combat and control insect, acarine, mollusc and nematode pests. In particular the present invention relates to imidazolines with alkyl and fluoro substituents. | 2010-05-13 |
20100120883 | NOVEL COMPOUNDS - The present invention provides compounds of formula (I): | 2010-05-13 |
20100120884 | USE OF DITHIINE-TETRACARBOXIMIDES FOR CONTROLLING PHYTOPATHOGENIC FUNGI - The present invention relates to the use of novel and of known dithiine-tetracarboximides for controlling phytopathogenic fungi, and to methods of controlling phytopathogenic fungi in plant protection, and to plant protection compositions comprising these dithiine-tetracarboximides. | 2010-05-13 |
20100120885 | Novel Derivatives of Psammaplin A, A Method For Their Synthesis And Their Uses For The Prevention Or Treatment Of Cancer - Derivatives of psammaplin A responding to formula (I), a method for their synthesis and their use for the preparation of a medicament for preventing and for treating a tumor or a cancer. Formula (I). | 2010-05-13 |
20100120886 | ARYL-SUBSTITUTED SULFONAMIDES FOR THE TREATMENT OF COGNITIVE OR FOOD INGESTION RELATED DISORDERS - The present invention relates to aryl-substituted sulfonamides with 5-HT | 2010-05-13 |